Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Innovent will supply sintilimab for the collaborated clinical trial
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Furthering cell therapy ambition across oncology and autoimmune diseases
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Subscribe To Our Newsletter & Stay Updated
